Home » Stocks » CHEK

Check-Cap Ltd. (CHEK)

Stock Price: $1.44 USD -0.04 (-2.70%)
Updated May 10, 2021 3:21 PM EDT - Market open
Market Cap 104.26M
Revenue (ttm) n/a
Net Income (ttm) -13.85M
Shares Out 70.45M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $1.44
Previous Close $1.48
Change ($) -0.04
Change (%) -2.70%
Day's Open 1.51
Day's Range 1.40 - 1.51
Day's Volume 1,157,308
52-Week Range 0.24 - 4.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Why should you check out CHEK stock? An FDA approval, along with an impressive year-end capital position, provide a solid case for Check-Cap.

1 month ago - InvestorPlace

ISFIYA, Israel, March 19, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...

1 month ago - PRNewsWire

Check-Cap (CHEK) stock is heading higher on Monday after the company announced approval from the FDA for one of its devices. The post CHEK Stock: The Big FDA News That Has Check-Cap Shares Skyrocketing ...

1 month ago - InvestorPlace

Check-Cap Ltd (NASDAQ: CHEK) stock is moving higher on heavy volume in the premarket session after the FDA approved its Investigational Device Exemption (IDE) application, permitting Check-Cap to begin ...

1 month ago - Benzinga

ISFIYA, Israel, March 15, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...

1 month ago - PRNewsWire

The technology appears safe, but performance versus standard of care requires a larger, expensive study. It will take a couple years to get readouts from the pivotal US study, providing a lack of catalyst.

3 months ago - Seeking Alpha

Check-Cap Ltd. (CHEK) stock is on the rise Monday despite a lack of news from the maker of the C-Scan colorectal cancer screening device.

4 months ago - InvestorPlace

CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

ISFIYA, Israel, July 23, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the ...

9 months ago - PRNewsWire

CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

ISFIYA, Israel, June 5, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first an...

11 months ago - PRNewsWire

ISFIYA, Israel, May 27, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Sca...

11 months ago - PRNewsWire

CheckCap Ltd. (CHEK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

11 months ago - Zacks Investment Research

Check-Cap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Check-Cap announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.

1 year ago - Benzinga

About CHEK

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-bas... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 19, 2015
CEO
Guy Neev
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
CHEK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Check-Cap stock is "Buy" and the 12-month stock price forecast is 3.00.

Price Target
$3.00
Analyst Consensus: Buy